Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial